NDLI: Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR<sup>+</sup>/HER2<sup>-</sup> breast cancer treated with CDK4/6 inhibitors and endocrine therapy.

Please wait, while we are loading the content...

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR⁺/HER2^- breast cancer treated with CDK4/6 inhibitors and endocrine therapy.

Content Provider	Europe PMC
Author	Tagliaferri, Barbara Mollica, Ludovica Palumbo, Raffella Leli, Claudia Malovini, Alberto Terzaghi, Matteo Quaquarini, Erica Teragni, Cristina Maccarone, Stefano Premoli, Andrea Sottotetti, Federico
Copyright Year	2023
Abstract	BackgroundAdvanced breast cancer (ABC) is characterized by multidimensional clinical complexity that is usually not considered in randomized clinical trials. In the present real-life study, we investigated the link between clinical complexity and quality of life of patients with HR+/HER2− ABC treated with CDK4/6 inhibitors.MethodsWe evaluated multimorbidity burden assessed with the Cumulative Illness Rating Scale (CIRS), polypharmacy and patient-reported outcomes (PROs). PROs were assessed at baseline (T0), after 3 months of therapy (T1), and at disease progression (T2) using EORTC QLC-C30 and QLQ-BR23 questionnaires. Baseline PROs and changes between T0 and T1 were evaluated amongst patients with different multimorbidity burden (CIRS <5 and ≥5) and polypharmacy (<2 or ≥2 drugs).ResultsFrom January 2018 to January 2022, we enrolled 54 patients (median age 66 years, IQR 59–74). The median CIRS score was 5 (IQR 2–7), whilst the median number of drugs taken by patients was 2 (IQR 0–4). No changes in QLQ-C30 final scoring between T0 and T1 were observed in the overall cohort (p=0.8944). At T2, QLQ-C30 global score deteriorated with respect to baseline (p=0.0089). At baseline, patients with CIRS ≥5 had worse constipation than patients without comorbidities (p<0.05) and a lower trend in the median QLQ-C30 global score. Patients on ≥2 drugs had lower QLQ-C30 final scores and worse insomnia and constipation (p<0.05). No change in QLQ-C30 final score from T0 to T1 was observed (p>0.05).ConclusionMultimorbidity and polypharmacy increase the clinical complexity of patients with ABC and may affect baseline PROs. The safety profile of CDK4/6 inhibitors seems to be maintained in this population. Further studies are needed to assess clinical complexity in patients with ABC.This article is part of the Tackling clinical complexity in breast cancer Special Issue: https://www.drugsincontext.com/special_issues/tackling-clinical-complexity-in-breast-cancer/
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10291968&blobtype=pdf
ISSN	17451981
Journal	Drugs in Context [Drugs Context]
Volume Number	12
DOI	10.7573/dic.2023-1-7
PubMed Central reference number	PMC10291968
PubMed reference number	37378079
e-ISSN	17404398
Language	English
Publisher	BioExcel Publishing Ltd
Publisher Date	2023-06-20
Access Restriction	Open
Rights License	Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission. Copyright © 2023 Tagliaferri B, Mollica L, Palumbo R, Leli C, Malovini A, Terzaghi M, Quaquarini E, Teragni C, Maccarone S, Premoli A, Sottotetti F
Subject Keyword	breast cancer CDK4/6 inhibitors clinical complexity comorbidities polypharmacy quality of life real-life population
Content Type	Text
Resource Type	Article
Subject	Medicine Pharmacology Molecular Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2- breast cancer treated with CDK4/6 inhibitors and endocrine therapy.

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR⁺/HER2^- breast cancer treated with CDK4/6 inhibitors and endocrine therapy.